Physiologically relevant ALK (anaplastic lymphoma kinase) expression was not detected in human and mouse monocytes and macrophages, suggesting that the effects of bioactive compounds on stimulator of interferon genes (STING) activation may not depend on ALK.
confined to few areas in the brain or in the testis. Importantly, tissues rich in monocytes and macrophages such as peripheral blood, spleen, and lung have undetectable ALK expression (Fig. 1A) . To directly characterize ALK expression in monocytes and macrophages, we performed Western blot assays with the rabbit monoclonal antibody SP8 from Abcam on the same mouse cell lines largely used in Zeng et al. (1) , which are immortalized bone marrow-derived macrophages (iBMDMs) and murine macrophage-like RAW264.7 cells. We used three different protein extraction buffers, all yielding comparable results for ALK expression. The SP8 antibody specifically detected ALK in 293T cells transfected with a plasmid encoding for the mouse full-length Alk receptor as well as the EML4-ALK fusion protein generated by CRISPR-Cas9 from the endogenous mouse Alk gene in lung cancer cells (8) (Fig. 1B) . Surprisingly, this antibody did not detect any band corresponding to the mouse ALK receptor in iBMDMs or RAW264 cells (Fig. 1B) . We then blotted the same lysates with the F-12 antibody used by Zeng et al. (1) . This antibody was raised against an epitope mapping between amino acids 117 to 145 within the N-terminal extracellular domain of human ALK and recognized the transfected mouse ALK but not the EML4-ALK fusion that contains only the cytoplasmic portion of ALK. Strikingly, it failed to recognize any band consistent with ALK in iBMDMs or RAW264 (Fig. 1B) .
Next, we tested human peripheral blood mononuclear cells (PBMCs) and the human THP-1 cell line also used by Zeng et al. (1) to seek for ALK expression in human monocytes and macrophages. We used the FDA-approved D5F3 antibody for ALK detection (7) and neuroblastoma cells that express the endogenous human ALK as controls. As expected, the D5F3 antibody specifically recognized the ALK protein in neuroblastoma lines with a pattern consisted in two bands of 220 to 230 kDa and 130 to 140 kDa as previously reported, where the lower band corresponds to a cleavage product of the ALK receptor (9) . In contrast, no bands with such pattern were seen in PBMCs or THP-1 cells even after long exposure of the membrane (Fig. 1C) . When the same cell lysates were probed with the F-12 antibody used by Zeng et al. (1) , the antibody correctly detected the 220-to 230-kDa full-length ALK in neuroblastoma cells, but not the 130-to 140-kDa cleaved ALK protein that lacks amino acids 117 to 145. Unexpectedly, this antibody also recognized a band of approximately 190 to 200 kDa that was detected across all human cells (Fig. 1C) . However, this band is different from the pattern of ALK expression in neuroblastoma and was also seen in negative controls such as the ALK-negative Burkitt lymphoma cell lines Raji and Ramos (Fig. 1C) . In addition, expression data from the Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ ccle) did not show detectable ALK mRNA in THP-1 cells (Fig. 2) . To exclude an unexpected expression or cleavage of ALK in macrophages, we transduced human THP-1 cells with a retroviral vector encoding human ALK. Both the D5F3 and F-12 antibody recognized a band in ALK-transduced THP-1 cells, but not in THP-1 cells transduced with an empty vector, with a pattern similar to neuroblastoma cells. Again, the F-12 antibody recognized a lower band in all cell lines, including ALK-rearranged NSCLC and ALCL, that carry ALK fusions with different molecular weights (Fig. 1D) . We concluded that the 190-to 200-kDa band detected by the F-12 antibody in all human cells is nonspecific. Last, immunohistochemistry failed to detect ALK expression in normal macrophages surrounding ALK-rearranged NSCLC and ALCL (Fig. 1E) .
Notably, Zeng et al.
(1) performed both the library compound screening and all the experiments with LDK378 or AP26113 with an inhibitor concentration of 10 M. However, drug concentration is critical for selective ALK inhibition. For example, LDK378 is selective for ALK with a median inhibitory concentration (IC 50 ) of 200 pM but at higher concentrations inhibits other tyrosine kinases such as IGF-1R (IC 50 of 8 nM), with broad inhibition of several tyrosine kinases at concentrations above 100 nM (10) . Likewise, AP26113 has an IC 50 of 370 pM for ALK and of 24.9 nM for IGF-1R (11) . Therefore, when used at 10 M [such as in the experiments performed by Zeng et al. (1) ], it is likely that these compounds block multiple tyrosine kinases.
Together, our findings indicate that mouse and human monocytes and macrophages do not express detectable amounts of the ALK receptor. Thus, the interesting findings that LDK378 blocks CDN-induced STING activation in vitro, as well as polymicrobial sepsis or lipopolysaccharide-induced endotoxemia in vivo, may be explained by the activity of this compound against other kinase(s) different than ALK.
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